PATH | VRL
Menu

Find resources

Total results with these characteristics: 170

Disease: Human papillomavirus (HPV)

Page 2 of 9
Chapter 25: Education, Training, and Communication for HPV Vaccines

The authors of this article, which is a chapter in a monograph published in Vaccine, purport that as HPV vaccines come to market, they will face education and training challenges similar to those of other new vaccines, along with HPV-specific …

Author: Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M

Publication date: 2006

Coalition Building: A Cornerstone of National Advocacy, Policymaking and Effective Cervical Cancer Prevention Programs

This issue brief is written for civil society leaders seeking to expand access to cervical cancer prevention and control resources in their communities. These resources include HPV vaccines for young adolescents and established and new screening and …

Author: Cervical Cancer Action

Cold Chain Temperature Monitoring in Vietnam: Monitoring Ambient and Cold Chain Temperatures During Delivery of Human Papillomavirus Vaccine

This report summarizes findings from a temperature-monitoring study that gathered ambient temperature data during human papillomavirus (HPV) vaccine delivery in Vietnam. These data are compared to the known heat stability profile of the HPV vaccine …

Author: PATH, World Health Organization

Publication date: 2010

Comparative Evaluation of the Potential Impact of Rotavirus Versus HPV Vaccination in GAVI-Eligible Countries: A Preliminary Analysis Focused on the Relative Disease Burden

This article, published in BMC Infectious Diseases, reports on a study that aimed to provide early insight into how the comparative impact of different new vaccines could be assessed in resource-poor settings with respect to affordability, …

Author: Kim SY, Sweet S, Chang J, Goldie SJ

Publication date: 2011

Comprehensive Cervical Cancer Control: A Guide to Essential Practice - Second Edition

This publication provides a broad vision of what a comprehensive approach to cervical cancer prevention and control means. It outlines the complementary strategies for comprehensive cervical cancer prevention and control, and highlights the need for …

Author: World Health Organization

Publication date: 2014

Comprehensive Cervical Cancer Prevention and Control: A Healthier Future for Girls and Women

This World Health Organization Guidance Note advocates for a comprehensive approach to cervical cancer prevention and control and is aimed at senior policy makers and programme managers. It describes the need to deliver effective interventions …

Author: World Health Organization

Publication date: 2013

Conducting Formative Research for HPV Vaccination Program Planning: Practical Experience from PATH

From 2006 to 2011, PATH conducted demonstration projects in four low- and middle-income countries—India, Peru, Uganda, and Vietnam—to provide evidence for decision-making about public-sector introduction of human papillomavirus (HPV) …

Author: PATH

Publication date: 2012

A Cost Comparison of Introducing and Delivering Pneumococcal, Rotavirus and Human Papillomavirus Vaccines in Rwanda

This article, published in Vaccine, reports on a cost comparison of introducing multiple vaccines in a single country and then assessing the financial and economic impact at the time and implications for the future. The objective of the analysis was …

Author: Ngabo F, Levin A, Wang SA, et al.

Publication date: 2015

Cost-Effectiveness of Female Human Papillomavirus Vaccination in 179 Countries: A PRIME Modelling Study

This article, published in The Lancet Global Health, reports on a modeling study that assessed the cost-effectiveness and health effects of vaccinating girls against human papillomavirus (HPV) before sexual debut in terms of burden of cervical …

Author: Jit M, Brisson M, Portnoy A, Hutubessy R

Publication date: 2014

Costs of Introducing and Delivering HPV Vaccines in Low and Lower Middle Income Countries: Inputs for GAVI Policy on Introduction Grant Support to Countries

This article, published in PLoS ONE, describes the data and analysis shared with GAVI Alliance policymakers regarding their support of human papillomavirus (HPV) vaccine. The authors review why strategies and costs for HPV vaccine delivery are …

Author: Levin A, Wang SA, Levin C, Tsu V, Hutubessy R

Publication date: 2014

Current Global Pricing for Human Papillomavirus Vaccines Brings the Greatest Economic Benefits to Rich Countries

This article, published in Health Affairs, details an economic model that estimates the distribution of the economic surplus—the sum of all health and economic benefits of a vaccine, minus the costs of development, production, and …

Author: Herlihy N, Hutubessy R, Jit M

Publication date: 2016

Current Global Status and Impact of Human Papillomavirus Vaccination: Implications for India

This article, published in the Indian Journal of Medical Research, discusses the efficacy and safety of human papillomavirus (HPV) vaccines, the current status of their introduction in National Immunization Programmes (NIPs), and the relevance of …

Author: Sankaranarayanan R, Bhatla N, Basu P

Publication date: 2016

Current Initiatives in Cervical Cancer Prevention

This fact sheet summarizes PATH's current work in cervical cancer prevention. Since PATH began to focus on cervical cancer in 1991, its portfolio has expanded to cover the full range of technologies and approaches for the prevention of cervical …

Author: PATH

Publication date: 2016

Delivering Cervical Cancer Prevention in the Developing World

This report highlights new partnerships and innovations in cervical cancer prevention and treatment. It also provides profiles of success in increasing access to HPV vaccines and treatment from around the world, with country spotlights on Mexico, …

Author: Women Deliver

Publication date: 2011

Delivery Cost of Human Papillomavirus Vaccination of Young Adolescent Girls in Peru, Uganda and Viet Nam

This article, published in the Bulletin of the World Health Organization, aimed to estimate the incremental delivery cost of human papillomavirus (HPV) vaccination of young adolescent girls in three countries. They found that the delivery cost per …

Author: Levin CE, Minh HV, Odaga J, et al.

Publication date: 2013

Diseases and the Vaccines that Prevent Them: For Parents of Preteens and Teens (7 Through 18 Years Old)

This series of fact sheets describes symptoms of infection as well as the benefits and risk of vaccination for several diseases, specifically for vaccines recommended for children aged 7 to 18 years. There are two types of fact sheets provided. …

Author: US Centers for Disease Control and Prevention

Efficacy and Safety of Human Papillomavirus Vaccine for Primary Prevention of Cervical Cancer: A Review of Evidence From Phase III Trials and National Programs

This article, published in the South Asian Journal of Cancer, discusses the justification of human papillomavirus (HPV) vaccination in the backdrop of the natural history of cervical cancer, the mechanism of action of the vaccines, and efficacy and …

Author: Basu P, Banerjee D, Singh P, Bhattacharya C, Biswas J

Publication date: 2013

Efficacy of Fewer Than Three Doses of an HPV-16/18 AS04-Adjuvanted Vaccine: Combined Analysis of Data From the Costa Rica Vaccine and PATRICIA Trials

This article, published in The Lancet Oncology, reports on a study to evaluate the efficacy of fewer than the recommended three doses of human papillomavirus (HPV)-16/18 vaccine four years after vaccination. The authors found that one and two doses …

Author: Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al.

Publication date: 2015

Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation

This article, published in the Journal of Infectious Diseases, reports on a post hoc analysis of the Phase 3 PATRICIA (PApilloma TRIal against Cancer In young Adults) trial that was performed to ascertain whether protection against low-risk human …

Author: Szarewski A, Skinner SR, Garland SM, et al.

Publication date: 2013

Efficacy, Safety, and Immunogenicity of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Women Older Than 25 Years: 4-Year Interim Follow-Up of the Phase 3, Double-Blind, Randomised Controlled VIVIANE Study

This article, published in The Lancet, discusses the results of an efficacy, safety, and immunogenicity study of the human papillomavirus (HPV) 16/18 vaccine in adult women. The results showed that in women older than 25 years, the HPV 16/18 vaccine …

Author: Skinner SR, Szarewski A, Romanowski B, et al.

Publication date: 2014

Page 2 of 9